Similarly, CTLA‐4 inhibition—either alone or in combination with PD‐1 blockade—has yielded limited clinical activity in B‐cell lymphomas,66, 67, 68 further underscoring the restricted efficacy of checkpoint inhibition in this disease. This evidence concerns the gene PDCD1 and B-cell non-Hodgkin lymphoma.